China Manufacturer Roadmap to Thai FDA Registration in Six Steps

1. Key takeaways

For a Chinese manufacturer, entering Thailand takes six steps, and the order of those steps matters as much as their content. The sequence runs from classification through licensing architecture, establishment licence, dossier preparation, submission and certification, and finally post-market maintenance. Each step has its own hard constraints, and the two that most often derail timelines are the establishment licence inspection and Thai-language localisation, not the review itself. The sections below set out the sequence, the speed levers and the reuse rules in the order a project team will actually encounter them.

• Step one, classification confirmation: determine Class 1 to 4 under the MoPH classification notification B.E. 2562, and for borderline products request a formal classification confirmation from the Thai FDA first.
• Step two, licence-holding structure: choose among distributor-held licensing, an independent licence holder (ILH) and setting up a Thai company.
• Step three, obtain the establishment licence: the licence-holding entity must first obtain the importer establishment licence, including the on-site inspection.
• Step four, prepare the dossier: simplified documents for Class 1; for Class 2 to 4, a CSDT dossier including ISO 13485, risk analysis, clinical evidence where applicable, and labels and instructions for use.
• Step five, filing and certification: submit through e-Submission and obtain the listed, notified or licensed certificate; each import shipment additionally requires an LPI.
• Step six, post-market maintenance: vigilance reporting, change management, renewal within the annual October to December window, and labelling and advertising compliance. Registration is not the finish line; obligations continue for the life of the certificate.
• On speed: Class 1 devices on the Positive List have been auto-approved through e-Submission after submission and payment since January 2025, without manual review; Class 2/3 and Class 4 run standard review with official caps of 250 and 300 days; the Reliance pathway via Singapore HSA shortens review from the standard 150 working days to 60 working days and exempts expert review.

2. Legal basis

The pathway rules rest on the Thai FDA For Commercial Purpose process, Steps 1 to 7, the MoPH classification notification B.E. 2562 (2019), and the reliance notification of 4 June 2024 (B.E. 2567) with its list of reference authorities, which now includes Malaysia, whose MDA joined the reliance arrangement with an agreement signed on 6 October 2026. The reuse of existing CE or FDA material is permitted for technical content, but the dossier must be rearranged into the CSDT structure. The real value of prior approvals is pathway eligibility. Under the Abridged pathway, Class 2 to 4 devices approved at least 1 year earlier by the US FDA, an EU notified body, the TGA, Health Canada or Japan MHLW may omit some documents, namely the verification and validation summary, the risk analysis and the disposal documentation, and avoid expert review; WHO Prequalification counts only for IVDs on the same 1-year condition. Under the Reliance pathway, devices approved by Singapore HSA or Malaysia MDA can be used directly under the bilateral reliance plans, with no holding-period requirement at all. Note carefully that the two pathways have different conditions: Abridged requires the 1-year holding period, Reliance does not, so the available prior approvals determine which door is open.

3. Expert insights

Where does the time actually go? Three places. First, the establishment licence on-site inspection, whose scheduling is not controlled by the applicant and which must therefore be started earliest. Second, the first-time writing of a CSDT dossier, especially the risk management section, the verification and validation summary and the clinical evaluation. Third, Thai-language localisation: labels and instructions for use of home-use devices must be in Thai, and the B.E. 2568 labelling notification requires Thai labelling to be completed within 120 days after import. A practical estimate from programme experience is that managing the establishment licence plus Thai localisation as the critical path, rather than managing the submission as the critical path, reflects where calendar time is really consumed; these two items frequently take longer than the review itself. Locking the licence-holding structure, the site conditions and the Thai translation resources at project start is therefore the highest-leverage planning decision, because rework in any of these three areas delays the programme by months, which is precisely the failure pattern seen in projects that treated filing speed as the whole story.

4. Practical recommendations

• Fix the Thai classification before anything else, using the B.E. 2562 notification and, for borderline products, a formal classification confirmation request to the Thai FDA.
• Decide the licence-holding model, distributor-held, independent licence holder or own Thai company, at project start, since it determines who files and who inspects.
• Start the importer establishment licence, including site preparation and inspection, before dossier work begins.
• Audit existing CE and FDA documentation against the CSDT outline early, and check Abridged eligibility, a qualifying approval held at least 1 year, and Reliance eligibility, a Singapore HSA or Malaysia MDA approval, to select the fastest lawful route.
• Commission Thai translation for labels and instructions for use of home-use devices in parallel with dossier writing, so the 120-day post-import labelling deadline under B.E. 2568 is met without a scramble.
• Plan Class 1 Positive List products for auto-approval after e-Submission and payment, and plan Class 2/3 and Class 4 against the 250 and 300 day caps.

5. Verification checklist

• □ Thai FDA website For Commercial Purpose, full process Steps 1 to 7 (pending verification).
• □ MoPH classification notification B.E. 2562 (2019) confirmed (pending verification).
• □ Thai FDA reliance notification of 4 June 2024 (B.E. 2567), list of reference authorities (pending verification).
• □ Announcement of Malaysia MDA joining the reliance arrangement, signed 6 October 2026 (pending verification).
• □ MoPH labelling notification B.E. 2568 (2025), 120-day post-import labelling grace period (pending verification).
• □ Thai FDA announcement of Class 1 automatic approval, January 2025 (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com